Given the global surge in autoimmune diseases, it is critical to evaluate emerging
therapeutic interventions. Despite numerous new targeted immunomodulatory therapies …

Systemic lupus erythematosus (SLE), the prototype of systemic autoimmune diseases is
characterized by extreme heterogeneity with a variable clinical course. Renal involvement …

Probiotics, prebiotics, and postbiotics can significantly influence B-cell-related diseases
through their immunomodulatory effects. They enhance the immune system's function …

В спектре механизмов хронического воспаления центральное место занимают два
фундаментальных патологических процесса-аутоиммунитет и аутовоспаление …

Background: Lupus osteoarthritis is a disabling complication of systemic lupus
erythematosus (SLE) caused by persistent inflammation and biomechanical factors. The …

Background This study analyzed the incidence, characteristics, and mortality risk associated
with cryptogenic organizing pneumonia (COP) among hospitalizations for systemic lupus …

Objectives To evaluate the effectiveness and safety of different B cell-targeting biological
agents combining with standard of care in patients with lupus nephritis (LN). Methods …

Combination therapy with glucocorticoids, cyclophosphamide, and plasmapheresis is
recommended as the standard treatment for anti-glomerular basement membrane (anti …

Background Telitacicept, a new biological agent, was approved in China for treating
systemic lupus erythematosus (SLE) in 2021. Its optimal dosing for treating SLE remains …

The prevalence and burden of autoimmune and autoantibody mediated disease is
increasing worldwide, yet most disease etiologies remain unclear. Despite numerous new …